Literature DB >> 16364390

The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen.

Alvin Eisner1, Lisa J Incognito.   

Abstract

This study compared color appearance data for two populations of middle-aged women: (1) women using the selective estrogen receptor modulator tamoxifen as adjuvant therapy following successful treatment for early-stage breast cancer, and (2) healthy amenorrheic (peri- or post-menopausal) control subjects not using any hormonally acting medications. A 3-alternative forced-response paradigm (with "blue", "lavender", or "white" as the allowable responses) was used for assessing the perceived color of 440-nm foveal test stimuli superimposed on a larger 3.6 log td 580-nm background. In contrast to the control subjects, the majority of tamoxifen users described the test stimuli as "white", whether at threshold or slightly suprathreshold. Threshold-sensitivity measurements themselves appeared less effective for distinguishing between subject groups. The results show that a simple color-naming procedure can reveal alterations of foveal short-wavelength-sensitive cone-mediated visual function that are common among tamoxifen users.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364390     DOI: 10.1016/j.visres.2005.11.003

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  9 in total

1.  Evaluation of multiple neurotoxic outcomes in cancer chemotherapy.

Authors:  Bernard Weiss
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 2.  A review of exercise interventions to improve bone health in adult cancer survivors.

Authors:  Kerri M Winters-Stone; Anna Schwartz; Lillian M Nail
Journal:  J Cancer Surviv       Date:  2010-04-07       Impact factor: 4.442

3.  The color appearance of stimuli detected via short-wavelength-sensitive cones: comparisons with visual adaptation and visual field data for peri- or post-menopausal women under 70 years of age.

Authors:  Alvin Eisner; Maureen D Toomey
Journal:  Vision Res       Date:  2008-03-17       Impact factor: 1.886

4.  Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach.

Authors:  Kerri M Winters-Stone; Britta Torgrimson; Fay Horak; Alvin Eisner; Lillian Nail; Michael C Leo; Steve Chui; Shiuh-Wen Luoh
Journal:  Arch Phys Med Rehabil       Date:  2011-03-02       Impact factor: 3.966

5.  Variability in short-wavelength automated perimetry among peri- or postmenopausal women: a dependence on phyto-oestrogen consumption?

Authors:  Alvin Eisner; Shaban Demirel
Journal:  Acta Ophthalmol       Date:  2011-05       Impact factor: 3.761

Review 6.  Chemobrain: a translational challenge for neurotoxicology.

Authors:  Bernard Weiss
Journal:  Neurotoxicology       Date:  2008-04-09       Impact factor: 4.294

7.  Vitreo-retinal traction and anastrozole use.

Authors:  Alvin Eisner; Emily J Thielman; Julie Falardeau; John T Vetto
Journal:  Breast Cancer Res Treat       Date:  2008-08-20       Impact factor: 4.872

Review 8.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

9.  Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.

Authors:  Alvin Eisner; Maureen D Toomey; Julie Falardeau; John R Samples; John T Vetto
Journal:  Breast Cancer Res Treat       Date:  2007-01-27       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.